Is Novartis's ground-breaking Alzheimer's prevention study over-ambitious?
This article was originally published in Scrip
Novartis is to test two of its investigational anti-amyloid therapies in a novel approach to prevent or delay the onset of Alzheimer's in people at a genetic risk for developing the disease, but some experts are sceptical about the wisdom of the approach.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.